A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen
Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, h...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-06-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341463963369472 |
|---|---|
| author | A. G. Obrezan A. E. Filippov A. A. Obrezan |
| author_facet | A. G. Obrezan A. E. Filippov A. A. Obrezan |
| author_sort | A. G. Obrezan |
| collection | DOAJ |
| description | Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, hypertension, heart failure, while strokes in patients with AF and diabetes are more severe. Diabetes, in turn, causes the angiopathies and cardiopathy. There is a higher risk of both thrombotic and bleeding events in patients with AF and T2D. The article discusses the mutual burden of T2D and AF, as well as the risk scores for thrombotic, thromboembolic, and bleeding events. Anticoagulant therapy takes a special place in improving the prognosis in AF patients. Numerous studies and actual clinical practice have demonstrated the effectiveness of anticoagulants in the prevention of stroke and other comorbidities. |
| format | Article |
| id | doaj-art-a854fcfa8ca9476d99e750d5d07b98b5 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2021-06-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-a854fcfa8ca9476d99e750d5d07b98b52025-08-20T03:43:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202021-06-0126510.15829/1560-4071-2021-45083263A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimenA. G. Obrezan0A. E. Filippov1A. A. Obrezan2Saint Petersburg State University; LLC International Medical Center “SOGAZ”Saint Petersburg State University; LLC International Medical Center “SOGAZ”Saint Petersburg State University; LLC International Medical Center “SOGAZ”Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, hypertension, heart failure, while strokes in patients with AF and diabetes are more severe. Diabetes, in turn, causes the angiopathies and cardiopathy. There is a higher risk of both thrombotic and bleeding events in patients with AF and T2D. The article discusses the mutual burden of T2D and AF, as well as the risk scores for thrombotic, thromboembolic, and bleeding events. Anticoagulant therapy takes a special place in improving the prognosis in AF patients. Numerous studies and actual clinical practice have demonstrated the effectiveness of anticoagulants in the prevention of stroke and other comorbidities.https://russjcardiol.elpub.ru/jour/article/view/4508diabetesatrial fibrillationcomorbidityanticoagulants |
| spellingShingle | A. G. Obrezan A. E. Filippov A. A. Obrezan A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen Российский кардиологический журнал diabetes atrial fibrillation comorbidity anticoagulants |
| title | A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen |
| title_full | A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen |
| title_fullStr | A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen |
| title_full_unstemmed | A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen |
| title_short | A patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen |
| title_sort | patient with atrial fibrillation and diabetes selecting the optimal anticoagulant therapy regimen |
| topic | diabetes atrial fibrillation comorbidity anticoagulants |
| url | https://russjcardiol.elpub.ru/jour/article/view/4508 |
| work_keys_str_mv | AT agobrezan apatientwithatrialfibrillationanddiabetesselectingtheoptimalanticoagulanttherapyregimen AT aefilippov apatientwithatrialfibrillationanddiabetesselectingtheoptimalanticoagulanttherapyregimen AT aaobrezan apatientwithatrialfibrillationanddiabetesselectingtheoptimalanticoagulanttherapyregimen AT agobrezan patientwithatrialfibrillationanddiabetesselectingtheoptimalanticoagulanttherapyregimen AT aefilippov patientwithatrialfibrillationanddiabetesselectingtheoptimalanticoagulanttherapyregimen AT aaobrezan patientwithatrialfibrillationanddiabetesselectingtheoptimalanticoagulanttherapyregimen |